Zura Bio
ZURA
38 hedge funds and large institutions have $105M invested in Zura Bio in 2023 Q2 according to their latest regulatory filings, with 37 funds opening new positions, 1 increasing their positions, 0 reducing their positions, and 2 closing their positions.
425,250% more capital invested
Capital invested by funds: $24.7K → $105M (+$105M)
1,750% more first-time investments, than exits
New positions opened: 37 | Existing positions closed: 2
1,167% more funds holding
Funds holding: 3 → 38 (+35)
29.71% more ownership
Funds ownership: 0.09% → 29.81% (+30%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$26.5M |
| 2 |
SCM
Suvretta Capital Management
New York
|
+$22.9M |
| 3 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
+$20.3M |
| 4 |
AC
Armistice Capital
New York
|
+$7.63M |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$5.73M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$17.3K |
| 2 |
SAMU
SONA Asset Management (US)
New York
|
-$6.36K |
ZURA Hedge Fund Activity: Q2 2023 in Review
38 of the 6,383 institutional investors tracked by Wall St. Rank reported a position in Zura Bio (ZURA) for Q2 2023, worth a combined $105M — up 425,250% from $24.7K a quarter earlier.
Buyers outnumbered sellers: 37 funds opened new ZURA positions and 2 closed out — a net gain of 35 holders — while 1 added to existing stakes and 0 trimmed.
The largest buyer was Great Point Partners, opening a new position worth an estimated $26.5M. The largest seller was UBS Group, exiting entirely with an estimated $17.3K sold.
- 38 institutional investors held Zura Bio (ZURA) as of Q2 2023, up from 3 in Q1 2023.
- Funds reported $105M of Zura Bio stock for Q2 2023, up 425,250% quarter-over-quarter.
- 37 funds opened new Zura Bio positions in Q2 2023 and 2 closed out, a net change of +35 holders.
- The largest Zura Bio buyer in Q2 2023 was Great Point Partners, an estimated $26.5M added.
- The largest Zura Bio seller in Q2 2023 was UBS Group, an estimated $17.3K sold.
Based on aggregated 13F filings for Q2 2023.